Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pustular diseases and keratinocyte-myeloid synergy.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Severity, heterogeneity and systemic inflammation in psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Pioneers in dermatology and venereology: an interview with Prof. Enno Christophers.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Periodontitis and risk of psoriasis: another comorbidity.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis.

The British journal of dermatology·2015
Same author

Bimodal immune activation in psoriasis.

The British journal of dermatology·2013

Related Experiment Video

Updated: Jul 19, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Targeting T-cell subsets to achieve remission.

E Christophers1

  • 1Department of Dermatology, University of Kiel, Kiel, Germany. e.christophers@web.de

Journal of the European Academy of Dermatology and Venereology : JEADV
|June 11, 2003
PubMed
Summary

Alefacept therapy significantly improves psoriasis by targeting pathogenic CD45RO+ memory-effector T cells. This treatment leads to reduced disease severity and long-term remission in some patients.

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is associated with increased pathogenic CD45RO+ memory-effector T cells.
  • Alefacept is a fusion protein designed to target this specific T-cell subset.

Purpose of the Study:

  • To evaluate the selectivity and efficacy of alefacept in patients with chronic psoriasis.
  • To assess the correlation between alefacept treatment, T-cell reduction, and clinical outcomes.

Main Methods:

  • A randomized, placebo-controlled, double-blind study involving 229 patients with chronic psoriasis.
  • Intravenous administration of alefacept at varying doses or placebo weekly for 12 weeks.
  • Evaluation of Psoriasis Area and Severity Index (PASI) scores and T-cell populations (CD45RO+ and CD45RA+) post-treatment.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Jul 19, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Main Results:

  • Alefacept treatment resulted in significant PASI score reductions compared to placebo (up to 53% vs. 21% decline).
  • A dose-dependent reduction in peripheral blood CD45RO+ memory-effector T cells correlated with psoriasis improvement.
  • Long-term remission was observed in some patients, with 28 achieving clear or almost clear status 12 weeks post-therapy.
  • Alefacept was well-tolerated and nonimmunogenic.

Conclusions:

  • Alefacept effectively targets and reduces pathogenic CD45RO+ memory-effector T cells in psoriasis patients.
  • The reduction in this specific T-cell subset is linked to clinical improvement and remission.
  • Alefacept represents a promising therapeutic option for chronic psoriasis with a favorable safety profile.